Leading microRNA-based molecular diagnostics developer and provider Rosetta Genomics Ltd. announced it has executed a credentialing agreement with Three Rivers Provider Network, Inc. (TRPN) for the Rosetta Cancer Origin Test. Based in Chula Vista, Calif., TRPN is one of the United States’ largest supplemental preferred provider organizations (PPO), providing healthcare benefits to more than 10 million members throughout the country.
This represents the second credentialing agreement that has been executed between Rosetta and a U.S. PPO, which is a managed care organization of medical doctors, hospitals and other healthcare providers that has covenanted to provide healthcare at reduced rates to the clients of an insurer or third-party administrator. Now, together with Medicare reimbursement, the total number of covered lives – and for which the Rosetta Cancer Origin Test could be adjudicated as “in-network” – is more than 61 million, meaning one in five Americans are covered for the test.
“We continue to pursue additional agreements with other PPOs as they provide faster payment while maintaining acceptable levels of reimbursement, and also reduce costs incurred through appealing denials,” said Rosetta Genomics President and CEO Kenneth A. Berlin. “This has become increasingly important to our company as we continue to see a growing number of samples being processed and billed by our CLIA lab.”
“This agreement comes at a good time for Rosetta as it follows on our strong presence at ASCO 2013,” he continued,“where we significantly enhanced the awareness of the Cancer Origin Test among an audience of the world’s leading oncologists and researchers. In addition, positive trends in billable and processed samples for the Cancer Origin Test have led us to begin expansion of our sales territories from five to 12. The credentialing agreement with TRPN further enhances our ability to gain traction in the market and to further increase access of this test to patients with a CUP diagnosis.”
This expanded coverage reflects the importance of determining the tumor origin in difficult-to-diagnose metastatic cancers and cancer of unknown or uncertain primary (CUP), as more than 200,000 patients per year are presenting with CUP or would otherwise benefit from the Rosetta Cancer Origin Test. Determining the tumor origin is even more important as new, molecularly targeted cancer treatments are developed.
“We believe the Rosetta Cancer Origin Test can help physicians to accurately diagnose tumor origin in order to optimize treatment,” Berlin added.“The availability and accuracy of our Cancer Origin Test underscores why the uncertainty of CUP is no longer acceptable.”
For more information, visit the company’s Web site at www.rosettagenomics.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
